IAS 2017

Karine Lacombe of Saint-Antoine Hospital, Paris, at IAS 2017. Photo by Liz Highleyman, hivandhepatitis.com Karine Lacombe of Saint-Antoine Hospital, Paris, at IAS 2017. Photo by Liz Highleyman, hivandhepatitis.com

Hepatitis C treatment

Hepatitis C treatment is effective and feasible in Africa

Dzintars Gotham presenting at IAS 2017. Image credit: Enzo Poultreniez / http://aides.orgDzintars Gotham presenting at IAS 2017. Image credit: Enzo Poultreniez / http://aides.org

$90-$90-$90 target

Countries and donors should aim for new $90-$90-$90 target on HIV, hepatitis, TB drug prices, study shows

Karine Lacombe at IAS 2017. Photo by Steve Forrest/Workers' Photos/IASKarine Lacombe at IAS 2017. Photo by Steve Forrest/Workers' Photos/IAS

Treatment for people with HIV/HCV co-infection

Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection

infohep news

Editors' picks from other sources